Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (591-600 of 962) with videos related to

Pageof 97
Sort By:
JAMA Cardiology|May 30, 2019
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary SyndromesThomas J Povsic, E Magnus Ohman, Matthew T Roe, et al.
American Heart Journal|December 9, 2008
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosisShinya Goto, Deepak L Bhatt, Joachim Röther, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
American Heart Journal|June 15, 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) TrialYuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, et al.
JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.
Vascular Medicine (London, England)|June 20, 2012
An evidence-based score to detect prevalent peripheral artery disease (PAD)Sue Duval, Joseph M Massaro, Michael R Jaff, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 24, 2024
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G Goodman, Philippe Gabriel Steg, Michael Szarek, et al.
Circulation|May 18, 2026
Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT TrialJ Dawn Abbott, Jocelyne R Benatar, Colleen M Ballantyne, et al.
American Heart Journal|March 24, 2022
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCIGregory Ducrocq, Deepak L Bhatt, Jane J Lee, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER TrialAlex C Spyropoulos, Mark Goldin, Walter Ageno, et al.
Pageof 97

Showing results (591-600 of 962) with videos related to

Sort By:
Pageof 97
JAMA Cardiology|May 30, 2019
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary SyndromesThomas J Povsic, E Magnus Ohman, Matthew T Roe, et al.
American Heart Journal|December 9, 2008
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosisShinya Goto, Deepak L Bhatt, Joachim Röther, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
American Heart Journal|June 15, 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) TrialYuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, et al.
JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.
Vascular Medicine (London, England)|June 20, 2012
An evidence-based score to detect prevalent peripheral artery disease (PAD)Sue Duval, Joseph M Massaro, Michael R Jaff, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 24, 2024
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G Goodman, Philippe Gabriel Steg, Michael Szarek, et al.
Circulation|May 18, 2026
Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT TrialJ Dawn Abbott, Jocelyne R Benatar, Colleen M Ballantyne, et al.
American Heart Journal|March 24, 2022
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCIGregory Ducrocq, Deepak L Bhatt, Jane J Lee, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|September 1, 2022
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER TrialAlex C Spyropoulos, Mark Goldin, Walter Ageno, et al.
Pageof 97